Pharmaceutical Strategy (Pharma) Task Force
Mission: Accelerate Adoption by Healthcare Stakeholders of In Silico Medicine for Bringing New Medicine to Patients
As the European Authorities are defining the evolution of their pharmaceutical strategies for the next few years, it is crucial to include new and critical technologies for the future. In silico technologies are, without any doubt, an essential tool that should be part of the pharmaceutical future of Europe.
The Pharma Strategy Task Force is acting as a Center of Expertise for In Silico approaches with representatives from Academia and Industry to inform and guide global Competent Authorities in this challenging task and propose concrete avenues, and texts, to engage Europe, US and other regions in the Digitalisation of the Regulatory Pharmaceutical activities”.
- Address Regulatory Aspects of in silico medicine when used in Pharmaceuticals
- Advocate use of in silico medicine for Pharmaceuticals for stakeholders
- Increase confidence of Industry for use of in silico medicine for Pharmaceuticals
- Identify use of in silico medicine for (specific) target indications and target populations